



# **Points to Consider for Microbial Control in ATMP Manufacturing**



## **Points to Consider for Microbial Control in ATMP Manufacturing Team**

---

### **Authors**

---

**Friedrich von Wintzingerode**, PhD, Roche-Genentech (Co-chair)

**Marc Glogovsky**, ValSource, Inc. (Co-chair)

**Daniel Bice**, Adaptimmune Therapeutics, PLC

**Lori Dingleline**, Spark Therapeutics, Inc.

**Phil Duncanson**, PhD, AstraZeneca

**Irving Ford**, Adaptimmune Therapeutics, PLC

**David Roesti**, PhD, Novartis

**Thomas Schomogy**, Pfizer Inc.

**Christine Sherman**, Takeda

**Marsha Steed**, Resilience

# Points to Consider for Microbial Control in ATMP Manufacturing

ISBN: 978-1-945584-34-3

© 2022 Parenteral Drug Association, Inc.

All rights reserved.



# Table of Contents

<b>INTRODUCTION .....</b>	<b>1</b>	Q6-2: Is there regulatory support for reduced microbiological test volumes? .....	12
Scope.....	1	Q6-3: Are method suitability studies (qualification/ bacteriostasis & fungistasis) required for ATMPs?.....	13
<b>GENERAL CONSIDERATIONS.....</b>	<b>2</b>	Q6-4: How can product volume be preserved when performing suitability studies? .....	14
Control through Facility Design.....	2	<b>TOPIC 6.1: BIOBURDEN TESTING.....</b>	<b>15</b>
Control through Equipment and Instrumentation Design and Maintenance .....	2	Q6.1-1: What test methods should be used for ATMP bioburden testing? .....	15
Control through Analyst and Operator Gowning and Qualification .....	2	Q6.1-2: What volumes are required for bioburden test samples? .....	16
Control Confirmed by Microbiological Process Monitoring.....	2	Q6.1-3: What is an example test plan for ATMPs regarding bioburden sampling? .....	17
<b>TOPIC 1: INCOMING APHERESIS/LEUKAPHERESIS MATERIAL .....</b>	<b>3</b>	Q6.1-4: Do ATMPs require specific considerations regarding bioburden quality control sample hold time?.....	18
Q1-1: What are the risks of contamination during apheresis/leukapheresis collection? .....	3	<b>TOPIC 6.2: STERILITY TESTING.....</b>	<b>19</b>
Q1-2: Is the microbial contamination risk different for autologous than for allogeneic processes? .....	4	Q6.2-1: What test methods should be used for ATMP sterility testing? .....	19
Q1-3: When and where should microbiological testing of apheresis/leukapheresis be performed?.....	5	Q6.2-2: What is the appropriate sampling point for sterility release testing if drug product is stored frozen? .....	20
Q1-4: What are the key points of consideration when defining the apheresis/ leukapheresis microbial test plan? .....	6	Q6.2-3: Is sterility testing required for plasmids?.....	21
<b>TOPIC 2: ATMP STABILITY STUDIES .....</b>	<b>7</b>	Q6.2-4: What is an example test plan for ATMPs regarding sterility sampling? .....	22
Q2-1: What microbiological methods are recommended for ATMP stability studies?.....	7	<b>TOPIC 6.3: RAPID STERILITY TEST METHODS.....</b>	<b>23</b>
<b>TOPIC 3: MATERIALS USED TO MANUFACTURE ATMPs.....</b>	<b>8</b>	Q6.3-1: Which aspects should be considered when selecting a rapid sterility test method for ATMPs? .....	23
Q3-1: Are there specific microbiological considerations for materials used to manufacture ATMPs? .....	8	<b>TOPIC 7: ENDOTOXIN TESTING.....</b>	<b>24</b>
<b>TOPIC 4: GENERAL REQUIREMENTS FOR MICROBIOLOGICAL SAMPLES FOR ATMP TESTING.....</b>	<b>9</b>	Q7-1: Final product of most ATMPs represents a complex sample matrix. Which aspects must be considered for an appropriate endotoxin test?... 24	
Q4-1: What are the general requirements for ATMP product testing samples, reserve samples and retain samples, and validation samples? .....	9	Q7-2: Cell therapy products are manufactured in closed process equipment under aseptic conditions. Is endotoxin in-process testing needed for these products? .....	26
<b>TOPIC 5: ASEPTIC PROCESSING SIMULATIONS.....</b>	<b>10</b>	Q7-3: Is control of endotoxin via the incoming materials sufficient not to have to perform endotoxin in-process product testing for ATMPs?.....	27
Q5-1: Are there any specific requirements for aseptic process simulation (also known as media fill) for ATMPs? .....	10	<b>TOPIC 8: MYCOPLASMA TESTING .....</b>	<b>28</b>
<b>TOPIC 6: BIOBURDEN AND STERILITY TESTING .....</b>	<b>11</b>		
Q6-1: Why are the traditional bioburden and sterility test volumes a challenge for ATMPs?.....	11		

Q8-1: Is mycoplasma testing a mandatory requirement for ATMPs or can firms perform testing following a risk-based approach? ..... 28

Q8-2: What is the appropriate process step/sampling for testing mycoplasma? ..... 29

Q8-3: What are appropriate reference organisms for validation of mycoplasma testing? ..... 30

**TOPIC 9: ADVENTITIOUS VIRUS SAFETY ..... 31**

Q9-1: Do ATMPs require adventitious virus safety strategies different from those for traditional biologics manufacturing?..... 31

**REFERENCES..... 32**

**FIGURES AND TABLES INDEX**

**Table 6.1-3-1** Example Test Plan for ATMP Process and Product Bioburden Testing ..... 17



Bethesda Towers  
4350 East West Highway  
Suite 600  
Bethesda, MD 20814 USA  
Tel: +1 (301) 656-5900  
Fax: +1 (301) 986-0296  
E-mail: [info@pda.org](mailto:info@pda.org)  
Web site: [www.pda.org](http://www.pda.org)